NuoTai Bio and DeepModeling Forge Strategic Alliance to Redefine the Pharma Industry with AI

Recently,Sinopep Bio (688076.SH) Enters into a Comprehensive Strategic Cooperation with DP Technology`, Focus`AI Technology Empowers the Transformation of the Biopharmaceutical Industry, Building "Intelligent R&D-Precision Manufacturing-"Ecological Empowerment" Trinity Value System. This strategic cooperation is based on“Technology Empowerment, Value Co-creation”At the core, covering all dimensions such as platform co-construction, project implementation, and capital synergy, aiming to reshape the new drug research and development and production model, and cultivate new industry productivity.

Signing Ceremony Held on5Month7Day at DP Technology2025Held at the Developer Conference, Sinopep's Chief Investment Officer Li Shuang and Investment Director Zhao Zhenyuan met with DP Technology's founder and...CEO Sun Weijie and Li Qin, Partner and Senior Vice President of DP Technology, signed the agreement on behalf of both parties.

The contents of the strategic cooperation between the two parties are as follows:

DP Technology Assists Sinopep Allsino Bio Pharmaceutical Co., Ltd. in Building through Three PathwaysAI DrivenCRDMO System:1. CustomizationAI R&D Platform EnhancementR Endpoint Efficiency and Technical Barriers;2. Integrate experimental data to build a digital asset library, achieving full-chain intelligence across R&D, process, and production ends;3. Relying onBohrium The base is equipped with an intelligent engine to optimize the entire process of data interaction and device management, covering R&D.-Production-Sales of the entire business chain.

Advance Integration in Phases: Optimize operations and enhance efficiency in the short term, build an AI-driven pharmaceutical system with cyclic peptide conjugates as a breakthrough in the medium term, extend to the field of synthetic biology, and establish a DBTL closed loop and a full-chain biomanufacturing platform; in the long term, embed AI capabilities, develop cross-domain large models, and achieve multi-scenario integration and strategic leaps.

From Technical Incubation to Closed-loop of Commercial Value: Integrating Cloud Computing, Automation and Other Technologies to Build an Ecosystem, Establishing a Full-chain Empowerment System from Technology R&D to Commercial Transformation, Promoting AI Integration in Multiple Fields and Upgrading Ecological Synergy.

Tong Ziquan, Chairman of Sinopep Allsino Bio Pharmaceutical Co., Ltd., said:“DP TechnologyDP Technology is a global leader in AI-empowered biopharmaceuticals, and its deep insights into the AI field will become Sinopep’s technological ‘n+1 power’. We look forward to this strategic cooperation achieving intelligence across all business segments and service areas of Sinopep Bio, keeping the group always aligned with DP Technology, and jointly becoming leaders of AI transformation in the industry!

Sun Weijie, founder and CEO of DP Technology, emphasized:“As a深耕者 in the细分领域 of biopharmaceuticals, Sinopep Allsino Bio Pharmaceutical Co., Ltd. has consistently driven development through innovation over the past decade, aligning seamlessly with DP Technology's mission of 'AI for Science.' We are honored to collaborate with Sinopep Allsino, integrating DP Technology's cutting-edge advancements in life sciences deeply into their entire chain of research, production, and sales to support intelligent business upgrades. Through complementary strengths and ecosystem co-construction, we believe this collaboration will accelerate the R&D and industrialization of innovative drugs, jointly forging a new future for the biopharmaceutical industry!

Sinopep Allsino Bio Pharmaceutical Co., Ltd. (Stock Code: 688076) was established in 2009 and listed on the STAR Market in 2021. Focusing on peptide drugs and small molecule chemical drugs, it strategically deploys oligonucleotide drugs. It combines independent research and development with CRDMO services. The company’s headquarters and research institute are located in Hangzhou, Zhejiang, with production bases in Lianyungang City and Jiande City, Hangzhou. The R&D team is led by experts from the Chinese Academy of Sciences, with overseas returnee doctors as the backbone, and has established a postdoctoral workstation.